ClinicalTrials.gg
CompletedNCT05120544EXTENDUpdated Oct 1, 2026Results posted

Expanding Technology-Enabled Nurse Delivered Chronic Disease Care

An interventional study of EXTEND Plus and EXTEND in Diabetes Mellitus, Type 2 and Hypertension, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Duke University · Not applicable, Interventional, and Health services research

How we know

Updated Oct 1, 2026Results postedStudy documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Diabetes Mellitus, Type 2 by Duke University — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Duke University.

Enrollment
8th of 26
220 · median 113
Started
2022
with 3 others
No phase
23 of 29
2 open now
Registered
22nd of 29
by date

Among the 29 studies in Diabetes Mellitus, Type 2 by Duke University, this one is the 8th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2022, is one of 23 with no phase, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 29 studies in Diabetes Mellitus, Type 2 by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Diabetes Mellitus, Type 2 by Duke University, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether the self-management of diabetes and hypertension can be improved with the use of mobile monitoring devices and nursing support.

Read the detailed description

EXpanding Technology-Enabled, Nurse-Delivered Chronic Disease Care (EXTEND) seeks to address evidence gaps that prevent practical use of mobile monitoring-enabled telehealth for clinic-refractory chronic diseases, with an initial focus on Persistent Poorly Controlled Diabetes Mellitus (PPDM) and hypertension. Because our population has already proven refractory to usual care, we will conduct an active comparator randomized trial (N=220) of two 12-month interventions: 1) mobile monitoring as a self-management tool (EXTEND); and 2) a nurse-delivered intervention incorporating mobile monitoring, self-management support, and medication management (EXTEND Plus). The medication management is a care team approach where the nurse works with a Pharmacist who has prescribing rights to optimize medications for the patients. This proposal will also allow us to examine a novel application for mobile monitoring technologies, as tools for predicting patient safety events.

Aim 1: Compare the effectiveness of the two 12-month EXTEND interventions for PPDM and hypertension. Hypothesis 1a: Compared to EXTEND, EXTEND Plus will improve primary (HbA1c) and secondary outcomes (e.g., blood pressure, weight, self-management measures) at 12 months; Hypothesis 1b: The relative effects of each intervention will be sustained at 24 months; Hypothesis 1c: Subgroup analyses will identify characteristics associated with high responsiveness to each intervention.

Aim 2: Guide scaling and dissemination of the EXTEND interventions by: (A) interviewing patients and stakeholders to clarify implementation barriers, facilitators and process requirements; (B) comparing intervention costs against potential reimbursement mechanisms; and (C) understanding the role of climate change and other social drivers of health on diabetes self-management and intervention engagement.

Aim 3: Explore the value of combining mobile monitoring and EHR data for predicting patient safety events (hospitalizations, emergency visits) in the EXTEND study cohort over 24 months. Participants will monitor their data using a suite of remote monitoring devices. Data will be analyzed with PACE by our team. If participants are randomized to the telehealth arm, these data will be reviewed by a RN during a telehealth visit to aid in clinical decision making.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Hypertension
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • type 2 diabetes by International Classification of Diseases (ICD) code or treatment with glucose-lowering medication or mention in clinical notes
  • Poor diabetes control as indicated by at least 1 greater than or equal to 8.0% with NO HbA1c less than 8.0% over the past 6 months
  • At least 1 appointment (office visit, appointment, initial consult, telemedicine) at primary clinic site over the past year
  • hypertension by ICD code or treatment with blood pressure-lowering medication or mention in clinical notes
  • poor hypertension control as indicated by a clinic systolic BP >140 AND/OR diastolic BP >90 over past year
  • use of an Apple iPhone or Android smartphone
  • can provide
  • can read/speak English
  • can provide informed consent

Exclusion criteria

Exclusion Criteria:

  • dementia, psychosis, or life-limiting illness
  • acute coronary event in past year
  • hypoglycemic seizure/coma over the past year
  • residence in a nursing home
  • use of an insulin pump
  • are or plan to become pregnant
  • unable or unwilling to use necessary technology to participate in study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Active comparator
    EXTEND

    EXTEND participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS). Participants can review data and trends within the device apps and modify self-management practices accordingly. The EXTEND group continues chronic disease care with their existing providers during the study, and are instructed at baseline to address management questions via their primary clinics' established avenues (as would be the case for any patient using mobile monitoring in clinical practice).

    Behavioral: EXTEND

  • Experimental
    EXTEND Plus

    EXTEND Plus participants receive 4 mobile monitoring devices to facilitate chronic disease self-management (glucometer, BP cuff, scale, accelerometer). Device data are transferred to Duke University Health System (DUHS) for use as part of nurse-delivered intervention combining mobile monitoring, self-management support, and medication management. The intervention is administered by clinical registered nurses (RNs) from Duke Primary Care (DPC) or Duke Endocrinology. For the medication management component, RNs work with a study PharmD affiliated with the participant's clinic. The PharmD determines if medication changes are needed, and prescribes accordingly. The RNs deliver EXTEND Plus via scheduled telephone encounters throughout the 12-month intervention. The initial encounter frequency is every two weeks, but may be extended to every four weeks for patients achieving treatment goals.

    Behavioral: EXTEND Plus

Interventions

  • BehavioralEXTEND Plus

    The EXTEND Plus approach builds patient self-management capacity by focusing on knowledge, self-efficacy, and goal setting (using an RN-delivered, module-based approach). All material is at an 8th grade reading level. Module topics include, but are not limited to, use of self-monitoring of blood glucose (SMBG), BP monitoring, developing a diet plan, medication adherence, hypoglycemia and hypotension self-management, and self-managing insulin. In addition, this intervention component addresses diet and activity self-management during each encounter.

  • BehavioralEXTEND

    EXTEND patients self-manage using data they collect during the study, and continue to receive standard behavioral counseling from primary providers.

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in blood sugar (glucose) attached to hemoglobin. Validated point-of-care or lab-based test.

    Time frame: Baseline, 3, 6, 9, 12, 18 and 24 months

Secondary outcomes

  1. Change in Systolic Blood Pressure

    Measure taken at clinic with standard arm cuff. Measurement is the average of two readings, on the same arm, taken 10 minutes apart.

    Time frame: Baseline, 3, 6, 9, 12, 18 and 24 months

  2. Change in Diastolic Blood Pressure

    Measure taken at clinic with standard arm cuff. Measurement is the average of two readings, on the same arm, taken 10 minutes apart.

    Time frame: Baseline, 3, 6, 9, 12, 18 and 24 months

  3. Change in Weight

    Measurement taken with lab scale, when patient is lightly clothed, shoes off.

    Time frame: Baseline, 3, 6, 9, 12, 18 and 24 months

  4. Change is Diabetes Distress Scale

    Measure of diabetes distress and burden using the Diabetes Distress Scale (DDS): 17 items, Scale 1-6. Scoring: Average. Higher score indicates higher distress level.

    Time frame: Baseline, 6, 12, 18 and 24 months

  5. Change in Diabetes Self-Management Questionnaire

    Measure of diabetes self-care. Diabetes Self-Management Questionnaire (DSMQ): 16 items, Scale 0-3. Scoring: Sum and transform to fall between 0-10. Higher score indicates more effective self-care.

    Time frame: Baseline, 6, 12, 18 and 24 months

  6. Change in Perceived Competence Scale

    Measure of diabetes self-efficacy and capacity. Perceived Competence Scale (PCS): 4 items, Scale 1-7. Scoring: average (1-7) Higher score indicates greater self-efficacy.

    Time frame: Baseline, 6, 12, 18 and 24 months

  7. Change in Medication Non-adherence

    Validated self-report measure using Voils' medication non-adherence measure. Voils 1. Full name: Voils Medication Nonadherence Measure 2. Construct: assesses how often a patient misses their prescribed medication and why 3. Scale range: 1-5 (the scale consists of 6 likert scale items ranging from 1=None of the time to 5=Every time. The total score is obtained by taking the mean of the items) 4. Higher scores indicate greater medication non-adherence. 5. There are no subscales.

    Time frame: Baseline, 6, 12, 18 and 24 months

  8. Change in Diabetes Knowledge

    Diabetes Knowledge Questionnaire (DKQ) is a 24-item validated measure. Diabetes Knowledge 1. Full name: Diabetes Knowledge Questionnaire 2. Construct: assesses diabetes knowledge 3. Scale range: 0-24 (the scale consists of 24 yes-no items that assess diabetes knowledge. One point is given for each item answered correctly.) 4. Greater scores indicate greater knowledge of diabetes 5. There are no subscales.

    Time frame: Baseline, 6, 12, 18 and 24 months

07

Results

Posted Oct 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneEXTEND PlusEXTEND
Started110110
Completed9190
Not completed1920
Withdrew: Withdrawn45
Withdrew: Lost to follow-up1515

Outcome measures

PrimaryChange in HbA1c

Change in blood sugar (glucose) attached to hemoglobin. Validated point-of-care or lab-based test.

Time frame:
Baseline, 3, 6, 9, 12, 18 and 24 months
Reported as:
Mean · percent change from baseline
Change in HbA1c
percent change from baselineEXTEND PlusEXTEND
Baseline to 3 months-0.8 ± 2.0-0.9 ± 1.7
Baseline to 6 months-1.0 ± 1.9-0.8 ± 2.3
Baseline to 9 months-1.3 ± 2.3-0.8 ± 2.5
Baseline to 12 months-1.1 ± 2.3-0.9 ± 2.3
Baseline to 18 months-1.1 ± 2.4-0.8 ± 2.6
Baseline to 24 months-1.1 ± 2.3-1.2 ± 2.5
Statistical analysis
  • EXTEND Plus vs EXTEND · Mean difference (net): -0.1 · 95% CI -0.5 to 0.2
  • EXTEND Plus vs EXTEND · Mean difference (net): -0.3 · 95% CI -0.7 to 0.2
  • EXTEND Plus vs EXTEND · Mean difference (net): -0.3 · 95% CI -0.9 to 0.2
  • EXTEND Plus vs EXTEND · Mean difference (net): -0.4 · 95% CI -1.0 to 0.3
  • EXTEND Plus vs EXTEND · Mean difference (net): -0.2 · 95% CI -0.9 to 0.4
  • EXTEND Plus vs EXTEND · Mean difference (net): 0.0 · 95% CI -0.6 to 0.7
SecondaryChange in Systolic Blood Pressure

Measure taken at clinic with standard arm cuff. Measurement is the average of two readings, on the same arm, taken 10 minutes apart.

Time frame:
Baseline, 3, 6, 9, 12, 18 and 24 months
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure
mmHgEXTEND PlusEXTEND
Baseline to 3 months-0.6 ± 20.6-2.4 ± 14.0
Baseline to 6 months-0.5 ± 21.51.0 ± 16.0
Baseline to 9 months-3.4 ± 20.02.0 ± 20.3
Baseline to 12 months-3.0 ± 20.82.1 ± 18.3
Baseline to 18 months-0.7 ± 20.90.9 ± 19.7
Baseline to 24 months-5.2 ± 25.51.8 ± 18.0
Statistical analysis
  • EXTEND Plus vs EXTEND · Mean difference (net): -0.8 · 95% CI -4.0 to 2.3
  • EXTEND Plus vs EXTEND · Mean difference (net): -1.9 · 95% CI -6.5 to 2.8
  • EXTEND Plus vs EXTEND · Mean difference (net): -3.0 · 95% CI -8.0 to 2.0
  • EXTEND Plus vs EXTEND · Median difference (net): -4.3 · 95% CI -9.9 to 1.2
SecondaryChange in Diastolic Blood Pressure

Measure taken at clinic with standard arm cuff. Measurement is the average of two readings, on the same arm, taken 10 minutes apart.

Time frame:
Baseline, 3, 6, 9, 12, 18 and 24 months
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure
mmHgEXTEND PlusEXTEND
Baseline to 3 months-0.2 ± 10.1-0.4 ± 7.8
Baseline to 6 months-0.4 ± 10.71.0 ± 8.7
Baseline to 9 months-1.6 ± 10.20.9 ± 10.4
Baseline to 12 months-0.4 ± 10.91.6 ± 9.2
Baseline to 18 months0.9 ± 10.31.7 ± 9.8
Baseline to 24 months-1.7 ± 12.31.5 ± 10.7
Statistical analysis
  • EXTEND Plus vs EXTEND · Mean difference (net): -0.9 · 95% CI -2.5 to 0.7
  • EXTEND Plus vs EXTEND · Mean difference (net): -1.5 · 95% CI -3.9 to 0.8
  • EXTEND Plus vs EXTEND · Mean difference (net): -1.8 · 95% CI -4.3 to 0.6
  • EXTEND Plus vs EXTEND · Mean difference (net): -1.8 · 95% CI -4.5 to 0.9
SecondaryChange in Weight

Measurement taken with lab scale, when patient is lightly clothed, shoes off.

Time frame:
Baseline, 3, 6, 9, 12, 18 and 24 months
Reported as:
Mean · lbs
Change in Weight
lbsEXTEND PlusEXTEND
Baseline to 3 months-2.3 ± 11.4-1.2 ± 20.2
Baseline to 6 months-4.6 ± 14.1-0.7 ± 15.5
Baseline to 9 months-7.5 ± 19.2-1.6 ± 17.5
Baseline to 12 months-8.2 ± 18.7-3.4 ± 18.1
Baseline to 18 months-9.9 ± 18.4-5.7 ± 21.7
Baseline to 24 months-9.0 ± 21.1-7.9 ± 22.4
Statistical analysis
  • EXTEND Plus vs EXTEND · Mean difference (net): -2.0 · 95% CI -4.4 to 0.5
  • EXTEND Plus vs EXTEND · Mean difference (net): -3.4 · 95% CI -7.2 to 0.3
  • EXTEND Plus vs EXTEND · Mean difference (net): -4.4 · 95% CI -8.8 to -0.0
  • EXTEND Plus vs EXTEND · Mean difference (net): -4.9 · 95% CI -10.1 to 0.3
SecondaryChange is Diabetes Distress Scale

Measure of diabetes distress and burden using the Diabetes Distress Scale (DDS): 17 items, Scale 1-6. Scoring: Average. Higher score indicates higher distress level.

Time frame:
Baseline, 6, 12, 18 and 24 months
Reported as:
Mean · score on a scale
Change is Diabetes Distress Scale
score on a scaleEXTEND PlusEXTEND
Baseline to 6 months-0.4 ± 0.8-0.4 ± 0.9
Baseline to 12 months-0.5 ± 0.9-0.4 ± 0.9
Baseline to 18 months-0.6 ± 1.0-0.4 ± 1.0
Baseline to 24 months-0.5 ± 1.0-0.5 ± 0.9
Statistical analysis
  • EXTEND Plus vs EXTEND · Median difference (net): -0.1 · 95% CI -0.2 to 0.1
  • EXTEND Plus vs EXTEND · Mean difference (net): -0.1 · 95% CI -0.4 to 0.1
SecondaryChange in Diabetes Self-Management Questionnaire

Measure of diabetes self-care. Diabetes Self-Management Questionnaire (DSMQ): 16 items, Scale 0-3. Scoring: Sum and transform to fall between 0-10. Higher score indicates more effective self-care.

Time frame:
Baseline, 6, 12, 18 and 24 months
Reported as:
Mean · score on a scale
Change in Diabetes Self-Management Questionnaire
score on a scaleEXTEND PlusEXTEND
Baseline to 6 months0.7 ± 1.50.5 ± 1.5
Baseline to 12 months0.9 ± 1.50.5 ± 1.4
Baseline to 18 months0.8 ± 1.50.6 ± 1.6
Baseline to 24 months0.8 ± 1.50.8 ± 1.6
Statistical analysis
  • EXTEND Plus vs EXTEND · Mean difference (net): 0.2 · 95% CI 0.0 to 0.4
  • EXTEND Plus vs EXTEND · Median difference (net): 0.4 · 95% CI 0.0 to 0.9
SecondaryChange in Perceived Competence Scale

Measure of diabetes self-efficacy and capacity. Perceived Competence Scale (PCS): 4 items, Scale 1-7. Scoring: average (1-7) Higher score indicates greater self-efficacy.

Time frame:
Baseline, 6, 12, 18 and 24 months
Reported as:
Mean · score on a scale
Change in Perceived Competence Scale
score on a scaleEXTEND PlusEXTEND
Baseline to 6 months0.4 ± 1.60.4 ± 1.6
Baseline to 12 months0.5 ± 1.70.3 ± 1.6
Baseline to 18 months0.5 ± 1.90.5 ± 1.7
Baseline to 24 months0.7 ± 1.60.7 ± 1.7
Statistical analysis
  • EXTEND Plus vs EXTEND · Mean difference (net): 0.1 · 95% CI -0.2 to 0.3
  • EXTEND Plus vs EXTEND · Mean difference (net): 0.1 · 95% CI -0.3 to 0.6
SecondaryChange in Medication Non-adherence

Validated self-report measure using Voils' medication non-adherence measure. Voils 1. Full name: Voils Medication Nonadherence Measure 2. Construct: assesses how often a patient misses their prescribed medication and why 3. Scale range: 1-5 (the scale consists of 6 likert scale items ranging from 1=None of the time to 5=Every time. The total score is obtained by taking the mean of the items) 4. Higher scores indicate greater medication non-adherence. 5. There are no subscales.

Time frame:
Baseline, 6, 12, 18 and 24 months
Reported as:
Mean · score on a scale
Change in Medication Non-adherence
score on a scaleEXTEND PlusEXTEND
Baseline to 6 months-0.3 ± 0.7-0.0 ± 0.6
Baseline to 12 months-0.3 ± 0.7-0.1 ± 0.8
Baseline to 18 months-0.2 ± 1.0-0.3 ± 0.7
Baseline to 24 months-0.3 ± 0.9-0.3 ± 0.7
SecondaryChange in Diabetes Knowledge

Diabetes Knowledge Questionnaire (DKQ) is a 24-item validated measure. Diabetes Knowledge 1. Full name: Diabetes Knowledge Questionnaire 2. Construct: assesses diabetes knowledge 3. Scale range: 0-24 (the scale consists of 24 yes-no items that assess diabetes knowledge. One point is given for each item answered correctly.) 4. Greater scores indicate greater knowledge of diabetes 5. There are no subscales.

Time frame:
Baseline, 6, 12, 18 and 24 months
Reported as:
Mean · score on a scale
Change in Diabetes Knowledge
score on a scaleEXTEND PlusEXTEND
Baseline to 6 months0.6 ± 2.50.7 ± 2.8
Baseline to 12 months0.9 ± 3.41.2 ± 3.2
Baseline to 18 months1.1 ± 3.81.5 ± 2.4
Baseline to 24 months1.4 ± 2.81.7 ± 3.0

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EXTEND Plus1/110 (0.9%)31/110 (28.2%)26/110 (23.6%)
EXTEND2/110 (1.8%)29/110 (26.4%)27/110 (24.5%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventEXTEND PlusEXTEND
Stroke/stroke evaluationNervous system disorders8/1105/110
Abdominal painGastrointestinal disorders3/1104/110
Cancer-related admissionNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/1100/110
Diabetic ketoacidosisMetabolism and nutrition disorders1/1103/110
Chest painCardiac disorders3/1103/110
Diabetic foot infectionInfections and infestations3/1101/110
Heart failure/fluid overloadCardiac disorders3/1100/110
Musculoskeletal or other painMusculoskeletal and connective tissue disorders3/1102/110
PancreatitisGastrointestinal disorders3/1102/110
HypotensionVascular disorders2/1102/110
Most frequent other events
Showing 10 of 22
Most frequent other events
EventEXTEND PlusEXTEND
Musculoskeletal or other painMusculoskeletal and connective tissue disorders12/11012/110
Abdominal painGastrointestinal disorders3/1104/110
Respiratory infectionRespiratory, thoracic and mediastinal disorders3/1104/110
Hyperglycemia without DKAMetabolism and nutrition disorders1/1103/110
Orthopedic injuryMusculoskeletal and connective tissue disorders3/1103/110
Skin/soft tissue infectionInfections and infestations3/1101/110
Chest painCardiac disorders1/1102/110
Nausea/vomitingGastrointestinal disorders2/1100/110
PancreatitisGastrointestinal disorders0/1102/110
HypertensionVascular disorders0/1101/110

Baseline characteristics

Age, Continuous
Age, Continuous(years)EXTEND PlusEXTENDTotal
Mean54.1 ± 10.154.9 ± 10.554.5 ± 10.3
Sex/Gender, Customized
Sex/Gender, Customized(Participants)EXTEND PlusEXTENDTotal
Male354479
Female7565140
Unknown011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EXTEND PlusEXTENDTotal
Black/African American7773150
White192847
Other/Unknown14923
Region of Enrollment
Region of Enrollment(participants)EXTEND PlusEXTENDTotal
United States110110220
HbA1c
HbA1c(percent)EXTEND PlusEXTENDTotal
Mean9.8 ± 1.79.8 ± 1.79.8 ± 1.7
08

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
09

References and documents

Publications

  • Crowley MJ, Lewinski AA, Yang Q, Hatch D, Palipana A, Bosworth HB, Kaufman BG, Chatterjee R, Pennington G, Matters D, Lee D, Urlichich D, Miller HN, German J, Sang S, Smith B, Kokosa S, Gregory P, Roberson CL, Canupp H, Shaw RJ. Expanding Technology-Enabled, Nurse-Delivered Chronic Disease Care : A Pragmatic, Randomized, Effectiveness-Implementation Trial. Ann Intern Med. 2026 Jul;179(7):968-979. doi: 10.7326/ANNALS-26-00132. Epub 2026 Jun 23. PubMed 42330500 ↗
  • Teo KM, Shaw RJ, Alexopoulos AS, Pennington G, Hatch D, Yang Q, Crowley MJ. Comparing the Effects of Diabetes-Specific and Overall Medication Regimen Complexity on Diabetes Distress. Sci Diabetes Self Manag Care. 2026 Apr;52(2):162-173. doi: 10.1177/26350106261422676. Epub 2026 Feb 25. PubMed 41738686 ↗
  • Lee D, Yang Q, Crowley MJ, Hatch D, Pennington G, Matters D, Shaw RJ. Chronic Illness Self-Management Latent Profiles in Individuals With Comorbid Type 2 Diabetes and Hypertension. Sci Diabetes Self Manag Care. 2025 Jun;51(3):250-261. doi: 10.1177/26350106251336311. Epub 2025 May 14. PubMed 40370006 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Our data will be made available for use by investigators not associated with the proposed study within 3 years after the primary results have been published. We will prepare a clear and searchable documentation of the database including a data dictionary, and its linkage to the pertinent study protocols and forms so that diverse investigators can make effective use of the data. For investigators interested in prospective collaborations, we will explore other options to provide support.

Supporting information: Study protocol, Analytic code

Time frame: Within 3 years of study data publication.

Access criteria: For all prospective opportunities (e.g., access to datasets, collaborative studies), we will widely advertise them on Duke Websites and at appropriate scientific meetings.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Aug 2025, 39 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 39 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2021
First posted
Nov 15, 2021
StartActual
Apr 21, 2022
Primary completionActual
Aug 13, 2025
CompletionActual
Aug 13, 2025
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedChange in blood pressureSystolic Blood PressureTime frame: Baseline, 3, 6, 9, 12, 18 and 24 months
  • EditedChange in weightDiastolic Blood PressureTime frame: Baseline, 3, 6, 9, 12, 18 and 24 months
  • EditedChange in medication nonMedication Non-adherenceTime frame: Baseline, 6, 12, 18 and 24 months
  • EditedChange in diabetes knowledgeWeightTime frame: Baseline, 6, 12, 18 and 24 months → Baseline, 3, 6, 9, 12, 18 and 24 months
  • EditedChange in hypertension knowledgeDiabetes KnowledgeTime frame: Baseline, 6, 12, 18 and 24 months
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedChange in blood pressureSystolic Blood PressureTime frame: Baseline, 3, 6, 9, 12, 18 and 24 months
    • EditedChange in weightDiastolic Blood PressureTime frame: Baseline, 3, 6, 9, 12, 18 and 24 months
    • EditedChange in medication nonMedication Non-adherenceTime frame: Baseline, 6, 12, 18 and 24 months
    • EditedChange in diabetes knowledgeWeightTime frame: Baseline, 6, 12, 18 and 24 months → Baseline, 3, 6, 9, 12, 18 and 24 months
    • EditedChange in hypertension knowledgeDiabetes KnowledgeTime frame: Baseline, 6, 12, 18 and 24 months

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05120544
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Nov 15, 2021
Start date
Apr 21, 2022
Primary completion
Aug 13, 2025
Completion
Aug 13, 2025
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Study contacts

Ryan J Shaw, RN, PhD
principal investigator · Duke University School of Nursing
Matthew Crowley, MD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion